Cargando…
GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer
BACKGROUND: Anomalous expression of glucose transporters (GLUTs) has been observed in a variety of tumor tissues. Although GLUT factors have been shown to have prognostic value for some cancer types, detailed bioinformatics investigation of the factors contributing to the prognostic prediction for p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797933/ https://www.ncbi.nlm.nih.gov/pubmed/35117597 http://dx.doi.org/10.21037/tcr.2020.03.50 |
_version_ | 1784641672823439360 |
---|---|
author | Zeng, Kai Ju, Gaoda Wang, Hao Huang, Jiangsheng |
author_facet | Zeng, Kai Ju, Gaoda Wang, Hao Huang, Jiangsheng |
author_sort | Zeng, Kai |
collection | PubMed |
description | BACKGROUND: Anomalous expression of glucose transporters (GLUTs) has been observed in a variety of tumor tissues. Although GLUT factors have been shown to have prognostic value for some cancer types, detailed bioinformatics investigation of the factors contributing to the prognostic prediction for patients with breast cancer (BC) has not yet been performed. METHODS: In this study, we examined the transcription levels of GLUT1, GLUT3, and GLUT4 and their associations with prognostic clinical data in patients with BC from the ONCOMINE database, using gene expression profiling interactive analysis (GEPIA), Kaplan-Meier (KM) plotter, and cBioPortal online tools. RESULTS: The transcription level of GLUT1 was significantly higher in the BC samples than in the normal tissues, whereas the levels of GLUT3 and GLUT4 were lower in the BC samples. The expression levels of GLUT1 and GLUT3 were associated with the cancer clinical stage. Consistently, survival analysis demonstrated that a high expression level of GLUT1 was associated with low relapse-free survival (RFS) in patients with BC, whereas high GLUT3 and GLUT4 levels predicted a longer RFS in these patients. CONCLUSIONS: Overall, these results suggest GLUT1 as an effective target of precision therapy, while GLUT3/4 are novel biomarkers for the prognosis of patients with BC. |
format | Online Article Text |
id | pubmed-8797933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-87979332022-02-02 GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer Zeng, Kai Ju, Gaoda Wang, Hao Huang, Jiangsheng Transl Cancer Res Original Article BACKGROUND: Anomalous expression of glucose transporters (GLUTs) has been observed in a variety of tumor tissues. Although GLUT factors have been shown to have prognostic value for some cancer types, detailed bioinformatics investigation of the factors contributing to the prognostic prediction for patients with breast cancer (BC) has not yet been performed. METHODS: In this study, we examined the transcription levels of GLUT1, GLUT3, and GLUT4 and their associations with prognostic clinical data in patients with BC from the ONCOMINE database, using gene expression profiling interactive analysis (GEPIA), Kaplan-Meier (KM) plotter, and cBioPortal online tools. RESULTS: The transcription level of GLUT1 was significantly higher in the BC samples than in the normal tissues, whereas the levels of GLUT3 and GLUT4 were lower in the BC samples. The expression levels of GLUT1 and GLUT3 were associated with the cancer clinical stage. Consistently, survival analysis demonstrated that a high expression level of GLUT1 was associated with low relapse-free survival (RFS) in patients with BC, whereas high GLUT3 and GLUT4 levels predicted a longer RFS in these patients. CONCLUSIONS: Overall, these results suggest GLUT1 as an effective target of precision therapy, while GLUT3/4 are novel biomarkers for the prognosis of patients with BC. AME Publishing Company 2020-04 /pmc/articles/PMC8797933/ /pubmed/35117597 http://dx.doi.org/10.21037/tcr.2020.03.50 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Original Article Zeng, Kai Ju, Gaoda Wang, Hao Huang, Jiangsheng GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer |
title | GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer |
title_full | GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer |
title_fullStr | GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer |
title_full_unstemmed | GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer |
title_short | GLUT1/3/4 as novel biomarkers for the prognosis of human breast cancer |
title_sort | glut1/3/4 as novel biomarkers for the prognosis of human breast cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797933/ https://www.ncbi.nlm.nih.gov/pubmed/35117597 http://dx.doi.org/10.21037/tcr.2020.03.50 |
work_keys_str_mv | AT zengkai glut134asnovelbiomarkersfortheprognosisofhumanbreastcancer AT jugaoda glut134asnovelbiomarkersfortheprognosisofhumanbreastcancer AT wanghao glut134asnovelbiomarkersfortheprognosisofhumanbreastcancer AT huangjiangsheng glut134asnovelbiomarkersfortheprognosisofhumanbreastcancer |